Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Roivant Sciences Ltd. Director's Dealing 2025

Mar 25, 2025

30587_dirs_2025-03-24_89cd9d1f-554e-46cb-9bac-8ead85e28140.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2025-03-20

Reporting Person: Venker Eric (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-03-20 Common Shares F 10945 $10.97 Disposed 874979 Direct
2025-03-20 Common Shares M 400000 $3.85 Acquired 1274979 Direct
2025-03-20 Common Shares S 315522 $11.06 Disposed 959457 Direct
2025-03-24 Common Shares M 602311 $3.85 Acquired 1561768 Direct
2025-03-24 Common Shares S 434478 $10.82 Disposed 1127290 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-03-20 Stock Option (Right to Buy) $3.85 M 400000 Disposed 2032-04-19 Common Stock (400000) Direct
2025-03-24 Stock Option (Right to Buy) $3.85 M 602311 Disposed 2032-04-19 Common Stock (602311) Direct

Footnotes

F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

F2: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024.

F3: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).